ADAM FIGLIOLA: Open Payments
NPI 1225586696 · CLERMONT, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,577 in 57 payments from 16 companies in 2025. Trend: 2023 $1,486 · 2024 $1,374 · 2025 $2,577
Food & beverage: $2,577
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $436 |
| Paratek Pharmaceuticals, Inc. | 6 | $389 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $361 |
| Axsome Therapeutics, Inc. | 3 | $265 |
| Lilly USA, LLC | 4 | $239 |
| Vanda Pharmaceuticals Inc. | 5 | $186 |
| Abbott Laboratories | 1 | $182 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Amgen Inc. | 1 | $110 |
| Alkermes, Inc. | 1 | $102 |
Products named: NUZYRA, CAPLYTA, VRAYLAR, Auvelity, FREESTYLE LIBRE 3, FANAPT, QULIPTA, MOUNJARO.
Industry payments across FL — which companies pay providers there.
